Pluvicto and lutathera injections
Ended Awarded Last action
- Contract number
- HT941026FE013
- Awardee
-
Novartis Pharmaceuticals Corporation UEI NG61ZA8TADW3
- Awarding agency
-
Defense Health Agency
Department of Defense
- Obligated
- $275,812
Award facts
- Contract value 100% obligated
- $275,812.41 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Contracting staff
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- East Hanover, NJ 07936, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Health Agency issued a $275,812.41 delivery order to Novartis Pharmaceuticals Corporation on December 19, 2025, for PLUVICTO and LUTATHERA injections under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB).
Place of performance is East Hanover, New Jersey. The order is firm fixed price with an ultimate completion date of January 2, 2026. No set-aside was used.
Quick answers
Who was awarded contract HT941026FE013?
HT941026FE013 was awarded to Novartis Pharmaceuticals Corporation by Defense Health Agency (Department of Defense) on December 19, 2025.
How much is contract HT941026FE013 worth?
The government has obligated $275,812 on HT941026FE013.
Is contract HT941026FE013 an order under another contract?
Yes. HT941026FE013 is a delivery order under 36F79720D0180, a federal supply schedule, on Pharmaceuticals and Drugs (FSS-61-IB).
Was contract HT941026FE013 competed?
The extent of competition for HT941026FE013 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award